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tially higher cost of ReSTOR® compared to a monofocal; this
did not hold true for ARRAY-SA40®. ReSTOR® improves
patients’ satisfaction and is a cost saving alternative versus spec-
tacles in patients requiring cataract surgery.
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OBJECTIVES: Assessment of the costs-of-illness of venous leg
ulcers treated in German wound centers. METHODS: A nation-
wide cross-sectional studywas performed in 31 specializedwound
centers, including ofﬁce- and clinic-based dermatologists, sur-
geons, GPs and internists. Patients with conﬁrmed diagnosis of
venous leg ulcer(s) were consecutively recruited, interviewed and
asked to ﬁll standardized questionnaires. Major outcomes param-
eters were the direct, indirect and intangible costs related to the leg
ulcers from the societal perspective. The patient case report forms
included questions on former treatment, health related quality
of life, patient-relevant treatment beneﬁt (PBI) and quality of
care. The physician questionnaire focused on clinical data,
co-morbidity, co-medication, wound status, resource consump-
tion and all relevant types of costs related to the treatment of
venous leg ulcers. RESULTS: In total, n = 218 patients (mean age:
69.8  12.0 years, median = 71) were enrolled, including 62.1%
women and 37.9% men. The median duration of ulceration was
7.0 years. The average total costs per patient summed up to €9569
per year, including €8658 of direct costs and €911 of indirect costs.
The major proportions of direct costs were statutory health
insurance costs (€7631) and out-of-pocket expenses (€1027). The
most cost-driving factor was inpatient treatment (€3568), fol-
lowed by non-drug treatment expenses (€740) and nursing fees in
home care (€212). Health-related quality of life was considerably
impaired in almost all of the patients, indicating high intangible
costs of illness. CONCLUSIONS: Venous leg ulcers in Germany
are associated with relevant direct, indirect and intangible costs
suggesting early and qualiﬁed disease management. are associated
with relevant direct, indirect and intangible costs suggesting early
and qualiﬁed disease management.
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OBJECTIVES: Severe chronic CHE is underreported in
Germany. Reported data refer to work-related disease only and
even these are incomplete (Diepgen & Schmidt 2002). However,
CHE has a huge impact on the working capacity of patients. We
therefore targeted to estimate the total costs of severe CHE in
Germany using epidemiological data in addition to reported
cases of occupational CHE. METHODS: In a ﬁrst step data on
151 patients with occupational CHE were analyzed to obtain
information on direct and indirect costs of CHE. In a second step
epidemiological information was used to create three groups of
patients: 1) DGUV-patients (German Statutory Accident Insur-
ance, payer for work-related diseases/accidents); 2) non-DGUV
but full-time working patients and 3) non-DGUV, non-full time
working patients. Cost assumptions per group were adjusted to
reﬂect differing reimbursement catalogues (DGUV vs. Statutory
Sick Funds), impact of work absenteeism and employment status.
Extensive scenario analyses with varying assumptions on costs
and epidemiology were conducted. RESULTS: Group 1 included
23,631 patients, group 299,735 and group 3,115,253. Per
patient costs per group amounted to €8799 in group 1, €5341 in
group 2 and €1035 in group 3. This results in total societal costs
of €860 million for severe, chronic CHE in Germany. Scenario
analyses showed a range of €348 million to €1.59 billion. 67% of
total costs were indirect costs, Statutory Sick Funds were the
payer for 15.5%, patients for 11.5% and DGUV for 6%. CON-
CLUSIONS: Total annual societal costs of severe chronic CHE
are enormous, despite the fact that CHE is not a life-threatening
disease. These costs are similar to the total costs of psoriasis,
colon or stomach cancer in Germany. The main cost component
are indirect costs. Effective therapeutic or preventive measures
would have a huge potential for cost savings.
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OBJECTIVES: Cataract is the principal cause of blindness
worldwide and surgery is the only effective treatment for this
condition. Several multifocal intraocular lenses (MFIOL) are cur-
rently available to reduce or eliminate the need for eyeglasses
after surgery. The objective of this survey was to collect data in
the Netherlands on the associated costs to society of wearing
spectacles after cataract surgery. This,information was requested
to support a health economics evaluation of MFIOLs.
METHODS: Cross-sectional survey of centers that recruited
patients who wore spectacles after cataract surgery and agreed to
complete a questionnaire. RESULTS: Forty-seven patients were
recruited with a mean age of 74.2 years and sex-ratio 2 females:
1 male. On average, they underwent cataract surgery 2.1 years
prior to recruitment. A total of 97.9% had a private insurance
which covered spectacle cost, at least partially, in 69.0% of the
cases. Spectacles were prescribed by an optometrist for 48.9%,
and glasses were multi focal in 76.7% of the cases (varifocal
44.7%). Spectacles were changed within 3 years in 50.0% of the
patients. Patients live an average of 11.5 km from their ophthal-
mologist and 5.8 k from their opticians. Mean spectacle cost
was €586.5, 43.7% being paid by private insurance. More than
80% of the patients wear glasses for watching TV, near reading,
going to movies or theater, driving, walking outside and visiting
friends. Dissatisfaction with glasses was rather rare at 13.7% of
the patients; 47.6% of the subjects expressed some willingness
to pay (at least €0.5 per day) to avoid wearing spectacles. CON-
CLUSIONS: Although almost half of all subjects had a private
health insurance, a large part of the cost was borne by patients.
The total economic burden of spectacles was not limited to the
spectacles; repeated travel related to eye care should also be
considered. There is some willingness to pay to be free of spec-
tacles in this population.
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OBJECTIVES: Otitis media (OM) is one of the most common
childhood diseases. By age 3-years, 50–85% of children have had
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